FTD is a term used to describe a group of neurocognitive disorders that encompass progressive dysfunction in executive functioning, behaviour, and language. There are three types of frontotemporal disorders (FTD): behavioural variant frontotemporal dementia (bvFTD), primary progressive aphasia (PPA), and movement disorders.
Frontotemporal Dementia Epidemiology Segmentation in the 7MM
- Total Diagnosed Prevalent Cases
- Type-specific Diagnosed Prevalent Cases
- Gene-specific Diagnosed Prevalent Cases
The total number of incident cases of Frontotemporal Dementia observed in the 7MM was observed to be 128K in the year 2021
The highest diagnosed Frontotemporal Dementia population accounting for 59K cases, was found in the United States, followed by EU5 (57K) and Japan (12K) in the year 2021.
The market size of Frontotemporal Dementia in the 7MM was found to be approximately USD 92 million in 2021
Frontotemporal Dementia Market Strengths
The absence of a marketed drug for Frontotemporal Dementia probably act as a strength for emerging drugs to lead the market once approved.
Frontotemporal Dementia Market Opportunities
Renewed interest in Frontotemporal Dementia research gives hope for future advancements that aim to increase diagnostic capabilities and expand treatment options through novel therapeutic targets.
- Latozinemab (AL001): Alector Inc.
- OBP-601: Transposon Therapeutics, Inc/Oncolys BioPharma Inc
- DNL593: Denali Therapeutics Inc
- BFT02: Passage Bio, Inc
- PR006: Prevail Therapeutics
- WVE-004: Wave Life Sciences